Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-01-23 3:48 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | Cowen Financial Products LLC | 3,647,430 7.05% | 567,078 (+18.41%) | View |
| 2022-04-22 10:54 am Purchase | 13G | Jounce Therapeutics, Inc. JNCE | Cowen Financial Products LLC | 3,080,352 5.96% | 3,080,352 (New Position) | View |
| 2022-02-14 4:52 pm Sale | 13G | Jounce Therapeutics, Inc. JNCE | Third Rock Ventures II, L.P. | 4,130,467 8.1% | -8,209,361 (-66.53%) | View |
| 2022-02-14 12:37 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | PFM Health Sciences, LP | 3,972,868 7.8% | 1,584,801 (+66.36%) | View |
| 2022-02-14 08:56 am Purchase | 13G | Jounce Therapeutics, Inc. JNCE | Deep Track Capital, LP | 4,000,000 7.81% | 143,537 (+3.72%) | View |
| 2022-02-14 08:55 am Purchase | 13G | Jounce Therapeutics, Inc. JNCE | RTW INVESTMENTS LP | 2,863,198 5.6% | 2,863,198 (New Position) | View |
| 2022-02-11 4:27 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | ORBIMED ADVISORS LLC | 2,200,200 4.3% | 2,200,200 (New Position) | View |
| 2022-02-10 09:28 am Sale | 13G | Jounce Therapeutics, Inc. JNCE | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 0% | -2,768,840 (Position Closed) | View |
| 2021-09-01 4:20 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | Deep Track Capital, LP | 3,856,463 7.53% | 3,856,463 (New Position) | View |
| 2021-04-05 5:26 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | BRISTOL MYERS SQUIBB CO BMY | 3,456,463 7.6% | 3,456,463 (New Position) | View |
| 2021-02-16 4:06 pm Sale | 13G | Jounce Therapeutics, Inc. JNCE | Third Rock Ventures II, L.P. | 12,339,828 31% | -939,292 (-7.07%) | View |
| 2021-02-01 2:13 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | PFM Health Sciences, LP | 2,388,067 6% | 2,388,067 (New Position) | View |
| 2021-01-29 4:12 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,768,840 6.95% | 2,768,840 (New Position) | View |
| 2020-10-26 4:33 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | GILEAD SCIENCES Inc GILD | 5,539,727 13.9% | 5,539,727 (New Position) | View |
| 2019-02-14 5:22 pm Sale | 13G | Jounce Therapeutics, Inc. JNCE | PFM Health Sciences, LP | 0 0% | -2,101,489 (Position Closed) | View |
| 2019-02-12 09:57 am Sale | 13G | Jounce Therapeutics, Inc. JNCE | WELLINGTON MANAGEMENT GROUP LLP | 1,510,754 4.62% | -364,108 (-19.42%) | View |
| 2018-12-10 09:02 am Sale | 13G | Jounce Therapeutics, Inc. JNCE | FMR LLC | 1,007,115 3.079% | -1,621,275 (-61.68%) | View |
| 2018-02-14 4:11 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | PFM Health Sciences, LP | 2,101,489 6.5% | 359,281 (+20.62%) | View |
| 2018-02-13 4:06 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | Third Rock Ventures II, L.P. | 13,279,120 41.2% | 13,279,120 (New Position) | View |
| 2018-02-08 12:03 pm Purchase | 13G | Jounce Therapeutics, Inc. JNCE | WELLINGTON MANAGEMENT GROUP LLP | 1,874,862 5.81% | 1,874,862 (New Position) | View |